Academic, corporate, health delivery, private foundation and governmental institutions have distinct missions and different systems of rewards. While each institution places its own relative value on respect, influence, power, position and money, individuals are rewarded most often because they command large constituencies, large budgets or because their work has great "impact" or novelty. Views of collaboration, openness, acceptance of risk, and acceptable timetables for evaluation of success can be quite different in the various institutional settings. Within these various institutional cultures lurk few overt but many covert obstacles. The Orphan Drug act and the FDA are notable in that they recognized obstacles which their actions presented to the development community and then made adjustments to reduce those obstacles.
a. Which institutional obstacles are significant impediments to developing drugs for monogenic diseases? b. How might these obstacles be removed, reduced, or avoided? c. Will development of drugs for monogenic skin diseases be more likely to succeed in one institutional setting rather than another? d. Is an altogether different institution needed?
Or more specifically: a. What are the obstacles at the FDA? b. In academia? c. In the corporate world? d. At private foundations? e. Is one institution better suited for this kind of work than another? f. Individual/professional obstacles: Is working on a rare disease an obstacle to personal advancement, and therefore an impediment to recruiting and retaining the talent needed to develop these treatments? Is collaborative work an impediment to personal advancement? Are the timetables for competitive, peer-reviewed funding (and professional advancement in academia) realistic for drug development? g. Intellectual property issues: Do IP issues prevent from getting needed collaboration or reagents? h. Setting priorities: Is the institutional culture nimble enough to promote timely and effective evaluation of results and resetting of priorities? i. Health delivery: Is our current US health delivery system an impediment relative to a national health system?
I. Institutional obstacles
• Which institution is the right place for translational research?
-Assume academia is a valid place (at least initial stages)
• Is translational research done by individuals/experts in a monogenetic disease? Or to break down the "translational research roadmap" to teams -Assume that one expert can play a large part (example BioMarin)
I. Institutional obstacles in Academia 
